Global markets for CNS biomarkers to reach $5.1 billion by 2017

The global central nervous system biomarker market presents an increasingly significant part of the overall pharmaceutical product market worldwide. Indeed, CNS biomarkers are critical tools for understanding disease mechanism, developing more effective treatments, and improving the quality of patient care. Rising consumer demand from China and India's growing middle classes, increasing number of tests reaching commercialization, and increasing global health concerns will drive growth in this market over the next five years.

BCC Research provides an in-depth analysis of the global central nervous system biomarkers market through its report Central Nervous System (CNS) Biomarkers: Technologies and Global Markets. According to the report, this global market was valued at $1.7 billion in 2011 and reached nearly $2 billion in 2012. BCC Research projects the market to grow to $5.1 billion by 2017, and register a five-year compound annual growth rate (CAGR) of 20.7% from 2012 to 2017.

Use this report to:

• Gain an overview of the global market for CNS biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
• Analyze global market trends, with data from 2010 through 2012, and projections of CAGRs through 2017.
• Evaluate technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
• Assess CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
• Review comprehensive company profiles of major players in the industry.

To order your copy of this report or to download the complimentary introduction chapter, click here.

RSS Feeds – Biotechnology